Inclusion Criteria:

- Participant has operable Stage I-IIIa invasive breast cancer of the following
subtype: ER-positive, HER2-negative tumor with histologic grade 2 or 3 and Ki67 ≥ 15%

- Tumor is at least 2 cm in diameter as assessed by physical or radiographic exam

- Participant consents to provide an existing tissue sample or to have a core needle
biopsy before drug administration

- Participant consents to provide tissue samples following drug administration by a
second core needle biopsy or from a surgical specimen

- Participant must have adequate organ function

Exclusion Criteria:

- Participant has received any prior chemotherapy, biological therapy or radiotherapy
for breast cancer

- Participant has a known hypersensitivity to the components of study drugs or their
analogs, including hypersensitivity to macrolide antibiotics (e.g. clarithromycin,
erythromycin, azithromycin).

- Participant has poorly controlled diabetes mellitus, or requires insulin for glucose
control.

- Participant is unable to swallow capsules and/or absorb oral medications

- Participant is pregnant or breastfeeding, or expecting to conceive children within
the projected duration of the study.

- Participant is known to be Human Immunodeficiency Virus (HIV)-positive

- Participant has known history of active Hepatitis B or C.

- Participant is concurrently using growth hormone (GH) or growth hormone inhibitors

- Participant has significant or uncontrolled cardiovascular disease, including heart
failure, unstable angina, or a myocardial infarction within the last 6 months